Search

Displaying results 4581 - 4590 of 5925 in total
  1. Drug

    Taspoglutide

    go.drugbank.com/drugs/DB14027
    Investigational

    In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects. As of May 2013 no new trials had been registered.

  2. Drug

    Orludodstat

    go.drugbank.com/drugs/DB21498
    Investigational

    Orludodstat has a monoisotopic molecular weight of 520.09 Da.

  3. Drug

    Revexepride

    go.drugbank.com/drugs/DB20324
    Investigational

    Revexepride has a monoisotopic molecular weight of 425.21 Da.

  4. Drug

    Levcromakalim

    go.drugbank.com/drugs/DB21154
    Investigational

    Levcromakalim has a monoisotopic molecular weight of 286.13 Da.

  5. Drug

    Lepzacitinib

    go.drugbank.com/drugs/DB21646
    Investigational

    Lepzacitinib has a monoisotopic molecular weight of 355.16 Da.

  6. Drug

    Luvometinib

    go.drugbank.com/drugs/DB21696
    Investigational

    Luvometinib has a monoisotopic molecular weight of 665.04 Da.

  7. Drug

    Pebezertinib

    go.drugbank.com/drugs/DB21705
    Investigational

    Pebezertinib has a monoisotopic molecular weight of 497.16 Da.

  8. Drug

    Inlexisertib

    go.drugbank.com/drugs/DB21713
    Investigational

    Inlexisertib has a monoisotopic molecular weight of 535.29 Da.

  9. Drug

    Rifamycin

    go.drugbank.com/drugs/DB11753
    ApprovedInvestigationalWithdrawn

    [L4800] This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801]

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  10. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    While it initially offered a promising therapy for patients experiencing relapsing or refractory disease,[A229363] umbralisib was withdrawn from the market due to safety concerns as the drug was associated

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates